Journal of Clinical Oncology
Articles in this Issue
Clinical outcomes of sequential androgen receptor pathway inhibitors (ARPIs) versus novel therapies in metastatic castration-resistant prostate cancer after progression on second-generation ARPIs: A systematic review and meta-analysis.
5075 Background: Most recent pivotal, randomized controlled trials (RCTs) testing novel therapies in ARPI pretreated mCRPC...
A first-in-human phase I/II study evaluating CTS3497, an MTA-cooperative PRMT5 inhibitor, in advanced or metastatic <i>MTAP</i> -deficient solid tumors.
3115 Background: Protein arginine methyltransferase 5 (PRMT5) methylates multiple protein substrates with a variety of bio...
Association of expression of m6A-modified ACLY immunotherapy resistance and poor survival in head and neck cancer.
e18094 Background: N6-methyladenosine (m6A) is the most common internal RNA modification and plays a significant role in p...
Response to cancer immunotherapy for p53 antibody-positive non-small cell lung cancer according to treatment regimen.
8589 Background: Cancer immunotherapy has enabled long-term survival in advanced non-small cell lung cancer (NSCLC), but t...
First-in-human study to evaluate the safety, tolerability, and PK of EIK1005, a novel WRN inhibitor in healthy participants.
e15110 Background: Cancers with deficient mismatch repair (dMMR) have high microsatellite instability (MSI-H) and are repo...
Application of a neoadjuvant 21-gene breast recurrence score assay to redirect surgical and systemic treatment pathways in early breast cancer: A multicenter prospective study.
596 Background: The 21-gene Oncotype DX Breast Recurrence Score assay is well established for determining use of adjuvant...
Body mass index and the risk of hematologic adverse events in HR+/HER2- breast cancer patients treated with CDK4/6 inhibitors.
e24150 Background: Cyclin-dependent kinase (CDK) 4/6 inhibitors has been established as the recommended therapy for hormon...
Pathologic complete response after neoadjuvant chemotherapy in triple-negative invasive lobular carcinoma: A meta analysis.
e12681 Background: Triple-negative invasive lobular carcinoma (TN-ILC) is a rare TNBC subtype with limited evidence to gui...
Longitudinal circulating tumor DNA surveillance as predictor of progression in advanced non-small-cell lung cancer with long-term benefit to immunotherapy.
8540 Background: Radiographic assessments often lag behind biological progression, and reliable biomarkers to stratify the...
Meaning, distress, and desire for hastened death in homebound adults with advanced cancer: A cluster analysis.
12071 Background: Patients with advanced cancer experience significant anxiety and depression exacerbating existential dis...
Durable treatment-free remission in CML beyond clinical trials: Lessons from a large single-center real-world experience.
6582 Background: Treatment-free remission (TFR) has become a major therapeutic objective in chronic-phase chronic myeloid...
Multi-omic profiling to clarify mechanisms of therapy-induced prostate cancer lineage plasticity.
e17077 Background: Prostate adenocarcinomas are the most common form of the disease. Targeting the androgen receptor (AR)...
Adaptive phase 2/3 study of EIK1001, a TLR7/8 dual agonist, in combination with pembrolizumab, as first-line therapy in participants with advanced melanoma (TeLuRide-006).
TPS9601 Background: Immune checkpoint inhibitors (ICIs), including anti-PD-1 antibodies, reverse tumor induced immune supp...
Nivolumab and ipilimumab as second or later line therapy in hepatocellular carcinoma: A retrospective study.
e16167 Background: Despite advances in first-line for systemic therapy in hepatocellular carcinoma (HCC), tumor progressio...
Economic burden of non-approved alternative therapies among patients with stage IV cancer: A prospective observational study.
TPS11201 Background: Complementary and alternative therapies, including herbal supplements and over-the-counter medication...
Knowledge distillation–enabled ResNet framework for hepatocellular carcinoma diagnosis on multiphase CT: Toward scalable global deployment.
4156 Background: Hepatocellular carcinoma (HCC) accounts for 85–90% of primary liver cancers and remains a leading cause o...
Comparative response assessment using PET-RANO 1.0 and RANO 2.0 in vorasidenib-treated <i>IDH</i> -mutant gliomas: The VORAFET study.
2073 Background: MRI-based response assessment may be suboptimal for capturing early treatment effects during isocitrate d...
Survival impact of post-transplant tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
e18599 Background: Although tyrosine kinase inhibitors (TKIs) have reduced the need for allogeneic hematopoietic stem cell...
Epidemiology of oral cavity cancer in women: Identifying the highest-risk age group.
e22594 Background: Oral cavity cancer has historically been more prevalent in men, largely attributed to tobacco use, alco...
Five-year follow-up of neoadjuvant chemoimmunotherapy in locally advanced head and neck squamous cell carcinoma.
6102 Background: Neoadjuvant chemoimmunotherapy has shown high rates of pathological response in locally advanced head and...
Aberrant somatic hypermutation in large B-cell lymphomas and its relationship to mutational signatures, including a novel haloalkane pattern.
7076 Background: Diffuse large B cell lymphoma (DLBCL) is a genetically complex disease, often characterized by the simult...
The early discharge clinic: A safe and efficient model for intensive outpatient management of hematologic malignancies.
e13558 Background: Hematologic malignancies often necessitate complex treatment regimens that can result in prolonged hosp...
BMS-986504 in patients (pts) with advanced solid tumors with homozygous <i>MTAP</i> deletion ( <i>MTAP</i> -del): Exploratory pharmacodynamic (PD) and biomarker analyses from CA240-0007.
3146 Background: The MTA-cooperative PRMT5 inhibitor BMS-986504 selectively binds to the PRMT5-MTA complex, a synthetic le...
Divergence between regulatory approvals and guideline recommendations in multiple myeloma: Helping solve physician’s dilemmas with a real-time updated evidence library.
e23047 Background: Despite the large number of trials and emergence of new therapies/combinations in multiple myeloma (MM)...
Phase II trial of anti-PD-1 monoclonal antibody and FOLFOXIRI combined with long-course radiotherapy as the total neoadjuvant treatment for proficient, mismatch repair, locally advanced low rectal cancer (PANFORTE).
3621 Background: The current standard treatment for locally advanced low rectal cancer (LALRC) achieves a complete respons...